Tonix Pharmaceuticals Holding (TNXP) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Tonix Pharmaceuticals Holding (TNXP) overview

Tonix Pharmaceuticals Holding (TNXP) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 13.1m and operating profit of USD -126m; the year-end share price was 15.62 USD and market capitalisation was USD 200m. Tonix Pharmaceuticals Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Tonix Pharmaceuticals Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 245mFY 2025
Share price15.62 USDFY 2025 year end
RevenueUSD 13.1mFY 2025
Operating profitUSD -126mFY 2025
Net earningsUSD -124mFY 2025
Market capitalisationUSD 200mFY 2025 year end

About Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals develops and commercializes therapies for central nervous system disorders, immunology, infectious diseases, and rare diseases. Its marketed products include TONMYA, a sublingual medicine for fibromyalgia in adults, and prescription products for acute migraine delivered by injection or nasal spray. The company also has clinical and preclinical development programs, including candidates for Lyme disease prevention, kidney transplant rejection, autoimmune diseases, and cocaine intoxication.

Generate the Tonix Pharmaceuticals Holding report

Tonix Pharmaceuticals Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Tonix Pharmaceuticals Holding and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Tonix Pharmaceuticals Holding

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.